Icure wins $2.85 mn lidocaine cataplasm order from Guatemala
The company will supply local anesthetics with a transdermal drug delivery system to the Servicio de Comercio Internacional
By Dec 19, 2023 (Gmt+09:00)
Macquarie eyes its 1st Korean data center valued around $722 mn
SK Inc. in talks to sell Pharmteco’s US CDMO plant to Novo Nordisk
S.Korea's LS Materials set to boost earnings ahead of IPO process
Galaxy Ring, new foldables set to steal the show at Samsung Unpacked Paris
POSCO gears up for carbon-free steelmaking with hydrogen
South Korea's Icure Pharmaceutical Incorporation announced on Tuesday that it signed a supply contract for the specialized local anesthetic lidocaine cataplasm with Guatemala's Servicio de Comercio Internacional.
Under the deal, Icure will deliver a total of $2.85 million worth of lidocaine cataplasm products over the next five years to Guatemala’s pharmaceutical company.
Icure's lidocaine cataplasm is applied directly to the affected area for convenient pain relief, utilizing a transdermal drug delivery system technology that allows the drug to penetrate continuously for 12 hours.
Icure specializes in the development and production of adhesive pharmaceuticals, such as patches, plasters, and cataplasms, based on this system technology.
Since receiving a special public listing for technology in 2018, Icure has been steadily preparing for overseas market entry, running a new factory in Wanju County, North Jeolla Province.
"I am pleased to have signed a supply contract for lidocaine cataplasm through swift negotiations with Servicio, discovered during the CPHI Barcelona in Oct. 2023," Icure CEO Lee Yeong-seok expressed his satisfaction with the latest contract.
Write to Yoo-Rim Kim at youforest@hankyung.com
-
Corporate strategyHyundai Glovis to spend $6.5 billion, seek M&As for expansion
Jun 28, 2024 (Gmt+09:00)
-
Korean chipmakersSouth Korea sets sights on fostering EDA tech to win HBM chip war
Jun 28, 2024 (Gmt+09:00)